China Gateway Biologics

China Gateway Biologics (CGB) is a contract manufacturing organization (CMO) and a subsidiary of ShangPharma, specializing in the development and large-scale production of biologic therapeutics. Based in Shanghai, China, the company provides a comprehensive suite of services including mammalian cell culture, process development, and fill-and-finish operations. CGB operates as the biologics manufacturing arm of Shanghai ChemPartner, supporting global pharmaceutical and biotech clients from preclinical stages through commercial launch. The company's state-of-the-art facilities in the Qidong Biopharma Industrial Zone utilize single-use bioreactor technology and adhere to international GMP standards. In addition to its service offerings, CGB is involved in the development of biologic assets such as SG12473, a bispecific antibody targeting CD47 and PD-L1 for the treatment of advanced cancers.